
Maximilian Diehn MD
Thoracic Cancer
Associate Professor, Radiation Oncology, Stanford University Medical Center
Join to View Full Profile
875 Blake Wilbur DrDept of Radiation Oncology Mc5847Stanford, CA 94305
Phone+1 650-723-6171
Dr. Diehn is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Education & Training
- Stanford Health Care-Sponsored Stanford UniversityResidency, Radiation Oncology, 2005 - 2009
- Stanford Health Care-Sponsored Stanford UniversityInternship, Internal Medicine, 2004 - 2005
- Stanford University School of MedicineClass of 2004
Certifications & Licensure
- CA State Medical License 2005 - 2025
- American Board of Radiology Radiation Oncology
Awards, Honors, & Recognition
- CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2011-2013
Clinical Trials
- Individualized Lung Tumor Stereotactic Ablative Radiotherapy (iSABR) Start of enrollment: 2011 Oct 21
- Molecular and Cellular Analysis of Breast Cancer
- Personalized Escalation of Consolidation Treatment Following Chemoradiotherapy and Immunotherapy in Stage III NSCLC in Stage III NSCLC Start of enrollment: 2021 Aug 25
Publications & Presentations
PubMed
- Association between Locoregional Failure and NFE2L2/KEAP1/CUL3 Mutations in NRG/RTOG 9512: A Randomized Trial of Radiation Fractionation in T2N0 Glottic Cancer.Li Guan, Pedro A Torres-Saavedra, Xiaobei Zhao, Michael B Major, Brittany J Holmes
Clinical Cancer Research. 2025-05-01 - Integrating ctDNA Analysis and Radiomics for Dynamic Risk Assessment in Localized Lung Cancer.Everett J Moding, Mohammad Shahrokh Esfahani, Cheng Jin, Angela B Hui, Barzin Y Nabet
Cancer Discovery. 2025-04-29 - 1 citationsAn ultrasensitive method for detection of cell-free RNA.Monica C Nesselbush, Bogdan A Luca, Young-Jun Jeon, Isabel Jabara, Catherine B Meador
Nature. 2025-04-16
Abstracts/Posters
- Circulating DNA for Molecular Response Prediction, Characterization of Resistance Mechanisms and Quantification of CAR T-Cells during Axicabtagene Ciloleucel TherapyMaximilian Diehn, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
- Interim Circulating Tumor DNA As a Prognostic Biomarker in the Setting of Interim PET-Based Adaptive Therapy for DLBCLMaximilian Diehn, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
- An Atlas of Clinically-Distinct Tumor Cellular Ecosystems in Diffuse Large B Cell LymphomaMaximilian Diehn, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
- Join now to see all
Press Mentions
- HMN 2025: How Cell-Free RNA Blood Check Identifies Early-Stage Cancers, Screens Therapy Resistance and Detects Tissue HarmApril 27th, 2025
- Liquid Biopsy Uses mRNA to Diagnose Cancer, Treatment Resistance, Tissue DamageApril 23rd, 2025
- Stanford Medicine Researchers Create RNA Blood Test to Detect Cancer and Other IndicatorsApril 21st, 2025
- Join now to see all
Grant Support
- Noninvasive imaging and blood biomarkers for personalized lung cancer immunotherapySTANFORD UNIVERSITY2024–2029
- Molecular Strategies to Widen the Therapeutic Index of RadiotherapySTANFORD UNIVERSITY2022–2027
- Molecular Strategies to Widen the Therapeutic Index of RadiotherapySTANFORD UNIVERSITY2022–2027
- Molecular Strategies to Widen the Therapeutic Index of RadiotherapySTANFORD UNIVERSITY2022–2027
- Molecular Strategies to Widen the Therapeutic Index of RadiotherapySTANFORD UNIVERSITY2022–2027
- Molecular Strategies to Widen the Therapeutic Index of RadiotherapySTANFORD UNIVERSITY2022–2027
- Circulating Genomic Determinants of Treatment Failure in Hodgkin LymphomaSTANFORD UNIVERSITY2021–2026
- Analysis of urine tumor nucleic acids for detection and personalized surveillance of bladder cancerSTANFORD UNIVERSITY2020–2025
- Analysis of urine tumor nucleic acids for detection and personalized surveillance of bladder cancerSTANFORD UNIVERSITY2020–2025
- Molecularly-based outcome and toxicity prediction after radiotherapy for lung cancerSTANFORD UNIVERSITY2020–2025
- Analysis of urine tumor nucleic acids for detection and personalized surveillance of bladder cancerSTANFORD UNIVERSITY2020–2025
- Analysis of urine tumor nucleic acids for detection and personalized surveillance of bladder cancerSTANFORD UNIVERSITY2020–2025
- Analysis of urine tumor nucleic acids for detection and personalized surveillance of bladder cancerSTANFORD UNIVERSITY2020–2025
- Imaging and circulating DNA markers to assess early response and predict treatment failure patterns in lung cancerSTANFORD UNIVERSITY2019–2024
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: